Pay-for-delay: how far will companies go to protect market exclusivity?

The drug development process is notoriously expensive – around $1.38bn on average – and from the standpoint of many pharma companies, ongoing patent protection is required to cover the costs. Credit: Courtesy of Zacharmstrong